Most Popular

    The Latest MacTel Research: What does it mean for patients?

    The Latest MacTel Research: What does it mean for patients?

    Scientists at the Lowy Medical Research Institute and their collaborators recently published an article describing a role for serine and toxic lipids in macular telangiectasia type 2.  The article, “Serine and Lipid Metabolism in Macular Disease and...

    Results of NT-501 Phase 2 Study Published

    Results of NT-501 Phase 2 Study Published

    January 16, 2019, Cumberland, RI and La Jolla, CA. The results of the NT-501 Phase 2 study sponsored by Neurotech Pharmaceuticals, Inc. (Neurotech) in collaboration with the Lowy Medical Research Institute (LMRI), have been published in the journal o...

    Neurotech Announces Positive Phase 2 Results in NT-501 (CNTF) for Macular Telangiectasia

    Neurotech Announces Positive Phase 2 Results in NT-501 (CNTF) for Macular Telangiectasia

    Neurotech Pharmaceuticals, Inc., in collaboration with the Lowy Medical Research Institute (LMRI), today announced 24-month results demonstrating that NT-501 delivering Ciliary Neurotrophic Factor (CNTF) has a beneficial effect in patients with Macul...